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Definitions 
Hydronephrosis – swelling of a kidney due to a build-up of urine.  
Ligate – tie up or otherwise close off (an artery or vessel). 
Nephrology – a specialty of medicine pertaining to the study of the kidney.  
Proximal – situated nearer to the center of the body or point of attachment. 
Renography – medical imaging of the kidneys. 
Ureter – the duct by which urine passes from the kidney to the bladder. 
Urology – a specialty of medicine pertaining to the study of the urinary system.  
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Abstract 
Ureteropelvic junction obstruction is a disease in which flow from the kidney to the 
bladder is obstructed for extended periods of time causing irreversible damage to the 
kidney. Current tests to detect kidney damage caused by obstruction are not effective 
until significant damage occurs. The purpose of this report is to identify a panel of 
biomarkers in urine to detect kidney damage earlier by analyzing data collected from a 
two-part study. Currently, two established urinary biomarkers to indicate kidney damage 
are NGAL and KIM-1. Biomarkers of interest in this study are CD13, CD10, and CD26. 
Results from the linear mixed model, from the murine animal study, determined that 
these biomarkers express significantly higher concentrations in damaged tissue. 
Predictive modeling on the clinical data indicated that CD13 and CD10 may provide 
more accurate predictions on UPJO patients than CD26.   
 1 
1 Introduction 
When a blockage occurs in the kidney or ureter for a short period of time the kidney will 
be able to recover. However, when the blockage occurs for many days or weeks damage 
to the kidney can occur; this is called obstructive nephropathy. Ureteropelvic junction 
obstruction (UPJO), as seen in figure 1.1, is a type of obstructive nephropathy that affects 
1 in 500 children [1]. 
 
Figure 1.1: Renal system and location of UPJO. Image source: 
http://www.brighamandwomens.org/Departments_and_Services/surgery/services/urology
/ureteropelvic-junction-obstruction.aspx?sub=6. 
 
Currently, urine tests to detect damage caused by obstruction rely on serum creatinine (a 
waste product that passes through the kidneys), which do not show abnormalities until 
kidney damage is greater than 50%. Recent studies have identified urinary biomarkers 
neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule-1 (KIM-1) 
 2 
as biomarkers in urine that may indicate damage prior to the current method [2-4]. 
However, the clinical applications of using these biomarkers to asses’ kidney damage is 
still undecided [5]. Therefore, it is a great of importance to develop a panel of biomarkers 
that can be used to better predict the stage of kidney damage. 
This report is a statistical consulting project in which I will be analyzing data collected 
from two studies aimed at identifying biomarkers in the urine that may indicate kidney 
damage. The first is an in vivo murine animal model study to verify the biomarkers of 
interest are present in higher quantities for damaged kidneys. The second is a clinical 
study of UPJO patients using data from a children’s hospital. Chapter 2 will give an 
overview of each study and the biomarkers being investigated, as well as the researchers’ 
needs from the analysis and their hypotheses. Chapters 3 and 4 will discuss specifics for 
each study and present the results of the murine animal model and clinical studies, 
respectively. Finally, chapter 5 will discuss the overall results from the study and 
conclusions to be made. 
 
 3 
2 Background 
The objective of this study is to develop a panel of biomarkers in urine that could predict 
kidney damage earlier than the current method. The biomarkers of interest for this study 
are CD13, CD10, and CD26. These biomarkers were chosen based off a previous pilot 
study [6]. Both the murine and human studies will have a control group and damaged 
group, in which the researchers are interested in seeing if the damaged group displays 
significantly higher concentrations of the biomarkers of interest. Data for these studies 
can be found in section 7. 
The murine study was conducted to provide in vivo data for Institutional Review Board 
(IRB) approval of the clinical study. Furthermore, the murine animal model allowed for a 
more precise quantification of kidney damage by sacrificing the animal, after urine 
collection, to allow direct observation of kidney damage using tissue staining methods. 
Therefore, murine models with significantly higher values for both the biomarkers of 
interest and tissue damage will support the hypothesis that the novel biomarkers indicate 
kidney damage. Tissue damage parameters were Trichrome, Percent Positive Glomeruli 
(PPG), Proximal Tubular Diameter (PTD), Glomerular Diameter (GD), and Terminal 
Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL). Trichrome is a tissue 
staining technique that will identify damaged kidney tissue, so higher values will be seen 
in damaged tissue. PPG is another tissue staining technique that will stain live kidney 
cells, so higher values are expected to be seen in undamaged tissue. PTD is a 
measurement within the kidney where higher values should associate with reduced flow 
due to the pressure build up that causes the proximal tubular to dilate. However, GD is 
 4 
opposite of PTD because scar tissue forms in damaged tissue causing GD to be reduced 
compared to undamaged tissue. TUNEL is a method to quantify damaged DNA, and 
hence tissue; this value should be higher in damaged tissue. 
The clinical study is the primary study of interest. Animal models give a good 
preliminary indication and are more cost effective, but do not fully represent what may be 
seen in humans. Therefore, the predictive model for biomarkers will be built on the data 
from the clinical study. Both established and novel biomarkers will be analyzed from 
urine collected in this study. Furthermore, the sex of the patient will also be included in 
the model because it has recently been made a requirement for NIH-funded research [7]. 
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3 Analysis of Murine Animal Study 
3.1 Data 
A murine animal model was used for this study, which consisted of four to six mouse 
samples. Unilateral ureteral obstruction (UUO) was performed on each mouse, in which 
either the right or left ureter (taken at random) was ligated to simulate renal damage, 
leaving the other ureter unligated to allow urine to flow freely from the kidney to the 
bladder on the one side. This allows for collection of paired samples, which were 
obtained by collecting secreted urine (unligated samples) and urine that had collected 
proximal to ligation (ligated samples) from the same mouse. Urine for each mouse 
sample was collected at day 2, 3, 4, 5, 7, and 10 after UUO and the concentrations of 
each biomarker were then measured. The mouse was sacrificed to assess tissue damage at 
the end of study, as discussed in Chapter 2.  
Data for this study was given to me during the initial meeting. The recommended sample 
size for each day, calculated by their previous statistical consultant, was ten to provide 
80% power to detect a group mean difference of 5,000 relative units (RU). However, the 
collected data contained at most six paired samples. Some days had only one paired 
observation due to missing data, as seen in figure 3.1. 
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Figure 3.1: Graphical representation of missing data for each variable. 
 
Any samples for a given day with less than three paired observations were not included 
for the hypothesis testing section (section 3.2). Boxplots were constructed to determine 
the spread of the data. As seen in figure 3.2, there are many outliers and it is difficult to 
tell the distribution with a small number of data points. The mean and variance, stratified 
by the day, can be found in section 9. Due to this observation, non-parametric methods 
were initially used. 
 7 
 
Figure 3.2: Boxplots of each variable separated by treatment. 
 
The hypothesis tests were done by day, so boxplots were made for each day as seen in 
section 8. From these plots, we do still have some concerns for normality, but there are 
less outliers (only NGAL). Therefore, paired t-tests were also performed to determine if a 
significant difference may exist, but it is noted that the p-values may not be credible due 
to the small sample sizes. Therefore, mixed linear models were used to obtain a better 
indication of how each biomarker relates to the treatment type (ligated or unligated). 
These results will be discussed in section 3.3. 
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3.2 Hypothesis Testing 
This study is expecting to see higher concentrations for all biomarkers in the ligated (L) 
samples versus the unligated (UL) samples, as discussed in Chapter 2. Therefore, the null 
(H0) and alternative (H1) hypothesis for the biomarkers discussed in this section are as 
follows: 
𝐻0: 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑛 𝐿𝑖𝑔𝑎𝑡𝑒𝑑 𝑆𝑎𝑚𝑝𝑙𝑒𝑠 =  𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑛 𝑈𝑛𝑖𝑔𝑎𝑡𝑒𝑑 𝑆𝑎𝑚𝑝𝑙𝑒𝑠  
𝐻1: 𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑛 𝐿𝑖𝑔𝑎𝑡𝑒𝑑 𝑆𝑎𝑚𝑝𝑙𝑒𝑠 >  𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛𝑠 𝑖𝑛 𝑈𝑛𝑖𝑔𝑎𝑡𝑒𝑑 𝑆𝑎𝑚𝑝𝑙𝑒𝑠  
The hypotheses are the same for all the tissue damage parameters except for PPG and 
GD, in which the alternative hypothesis is opposite due to UL values having the higher 
expected values, as discussed in Chapter 2. Data was collected in pairs, L and UL 
samples, so the difference between the paired samples was used.  
The results in this section are presented with both the standard significance level and also 
a significance level using a multiple comparsion correction, specifically the Bonferroni 
correction. This correction is designed to control the probability of rejecting at least one 
null hypothesis, or familywise error rate, when performing multiple hypotheses tests. For 
example, in section 3.2.1 we are doing 46 different tests so the probability of reject at 
least one null hypothesis is much higher than 0.05 even if these 46 null hypotheses are 
true when we set the significance level for each test as 0.05. For the Bonferroni 
correction, α/M is used as the significance level for each test, where α is the desired 
overeall significance level and M is the number of test. In our study, α=0.05 was used and 
the null hypothesis was rejected if the p-value was less than 0.05/M. 
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3.2.1 Non-Parametric Tests 
With a small number of observations per day, a non-parametric method, specifically the 
Wilcoxon Signed-Rank test, was used to determine if the difference is different from 
zero. Biomedical publications consider the rejection of null hypothesis to be p-values less 
than 0.05. Furthermore, it is typically noted in publications when a p-value is less than 
0.01 to indicate a stronger conclusion.  
For this test, we are assuming that L and UL samples are dependent, each mouse is 
randomly and independently drawn, the dependent variable is continuous, and the data is 
at least ordinal. The first two assumptions are met by the method used to collect the data, 
but it is noted that independence between mice may not be valid due to inbreeding. The 
dependent variable was a normal approximation to binomial for these tests, so a 
continuity correction was done to account for the approximation. All the data collected 
was continuous data, so the data meets the fourth assumption needed.  
The statistical software R was used to conduct this test. For the non-parametric test, the 
built-in function wilcox.test was used. This function inputs the data, alternative 
hypothesis, and a logical operator to indicate if data is paired, then it returns the test 
statistic (W) and p-value. The continuity correction is applied by default using this 
function. All the p-values from the analysis are summarized in table 3.1, where N/A 
indicates days that have less than 3 observations so the test was not performed. 
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Table 3.1: p-values from Wilcoxon Signed-Rank tests on mouse data. 
Biomarker 
Day 
2 3 4 5 7 10 
NGAL N/A 0.3125 0.125 0.01563* 0.2188 0.01563* 
KIM-1 N/A N/A N/A N/A 0.125 N/A 
CD13 N/A 0.25 0.125 0.625 0.125 0.0625 
CD10 N/A N/A N/A 0.0625 0.0625 0.0625 
CD26 N/A N/A 0.0625 0.0625 0.0625 0.0625 
Tissue Damage  
Trichrome 0.25 0.0625 0.0625 0.125 N/A N/A 
PPG 0.4375 0.0625 0.0625 0.0625 0.0625 0.0625 
PTD 0.9375 0.8125 0.1875 0.125 0.0625 0.0625 
GD 0.3125 0.0625 0.1875 0.0625 0.0625 0.0625 
TUNEL 0.4375 0.125 0.125 0.125 0.125 0.0625 
* = p-value < 0.05 
 
These results indicate that the only statistically significant difference is for the biomarker 
NGAL at day 5 and 10. This means that for the given data at those time points, NGAL is 
expressed in significantly higher concentrations for the ligated ureter, compared to the 
unligated one. The rest of the samples had insufficient evidence to detect a difference 
between ligated and unligated samples. Using a Bonferroni correction for multiple 
comparisons we obtain a significance level of 0.00109. Using this significance level, no 
results are considered significant. However, it is notable that many of the p-values are 
close to 0.05, which leads one to believe that a difference may exist, but is not detectable 
with the small sample sizes in this study. 
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3.2.2 Parametric Tests 
To see if a difference may exist in some of those, a paired t-test was also performed. 
DeWinter’s paper claims that a paired t-test can be valid for extremely small sample sizes 
if the within-pair correlation is high [8]. Furthermore, the t-test is robust to the normality 
assumption. Along with the other assumptions made in section 3.2.1 we must also assume 
that the L and UL populations have the same skewness and there are no influential 
outliers.  
To perform a paired t-test R’s built-in function t.test was used. This function allows for a 
paired t-test to be performed, which was used for the given data. This function has similar 
inputs as the wilcox.test function; a continuity correction is not required, but we do 
assume the variances to not be equal. The output gives the test statistic (t) and p-value as 
in the wilcox.test function. The p-values for the given data are presented in table 3.2, 
again N/A indicates days with less than 3 observations so the t-test was not performed. 
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Table 3.2: p-values from paired t-tests. 
Biomarker 
Day 
2 3 4 5 7 10 
NGAL N/A 0.1819 0.0375* < 0.001*** 0.2338 0.0942 
KIM-1 N/A N/A N/A N/A 0.0724 N/A 
CD13 N/A 0.1036 0.0766 0.7777 0.0262* 0.0997 
CD10 N/A N/A N/A 0.0226* 0.0034** 0.0364* 
CD26 N/A N/A 0.0121* 0.0216* 0.0147* 0.0025** 
Tissue Damage  
Trichrome 0.1501 0.0334* 0.0042** 0.0448* N/A N/A 
PPG 0.346 0.0968 0.0028** 0.0040** 0.014* 0.0048** 
PTD 0.8938 0.6248 0.1702 0.0822 0.0026** 0.0303* 
GD 0.1737 0.0152* 0.1655 0.0074** 0.0166* 0.0070** 
TUNEL 0.4024 0.0966 0.0573 0.0856 0.0319* 0.0234* 
* = p-value < 0.05; ** = p-value < 0.01; *** = p-value < 0.001 
 
The results in table 3.2 show what was suspected; some of the non-parametric p-values 
that were slightly greater than 0.05 have p-values less than 0.05 for the parametric 
method. Furthermore, only NGAL at day 5 is considered as significant when the 
Bonferroni correction is used. So, we now see a lot more significant observations 
compared to the non-parametric test, as indicated by the asterisk in the table. 
Furthermore, we see that there are no significant observations in day 2 and almost all of 
the day 10 observations are significant. This aligns with the hypothesized outcome that as 
time went on these biomarkers would be expressed in significantly higher amounts for 
the ligated samples. However, the commonly accepted methods for this test make the p-
values not very credible due to the inability to check assumptions needed for this test. 
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3.3 Mixed Linear Model 
Due to the small sample size and many of the days having observations less than three, 
mixed linear models were used to help determine the effect of each biomarker. The 
mixed linear model can consider all data together thus is potentially more powerful than 
the non-parametric method used in Section 3.2.1 and the t-test used in Section 3.2.2.  A 
mixed linear model consists of the fixed and random effects where the random effects can 
take account for the correlations of data within each mouse. The following mixed linear 
model in Equation 1 was used. 
Equation 1:     𝑌𝑖𝑗𝑘 =  𝛽0 + 𝛽𝑡 ∗ 𝑇𝑘 + (𝛼0𝑖 + 𝛼1𝑖 ∗ 𝑑𝑗) + 𝜀𝑖𝑗𝑘 
In this model, subscripts represent the sample (i = 1, 2, . . ., 6), day (j = 2, 3, 4, 5, 7, 10), 
or the treatment (k = L, UL). The overall intercept (𝛽0) and treatment effect (𝛽𝑡) are 
considered as the fixed effects. The intercept (𝛼0𝑖) and the slope for days 𝛼1𝑖 are 
considered as the random effect. We further assume that: (1) 𝛼0𝑖 and 𝛼1𝑖 are normally 
distributed. Specifically, 𝛼0𝑖 has a mean of 0 and variance of 𝜎0
2, 𝛼1𝑖 has a mean of 0 and 
variance of 𝜎1
2, and 𝛼0𝑖 and 𝛼1𝑖 have a correlation of 𝜌; (2) 𝛼0𝑖 and 𝛼1𝑖 are independent 
for different mouse. The error terms, 𝜀𝑖𝑗𝑘, are independent and are independent of 𝛼0𝑖 and 
𝛼1𝑖.  𝜀𝑖𝑗𝑘 is normally distributed and has a mean of and variance of 𝜎0
2.   
The mixed linear models were built using the R package lmerTest [9]. Within this 
package is the function lmer, which fits a mixed linear model. The formula for the mixed 
linear model used in R for this analysis is shown below (Equation 2): 
Equation 2:       𝑌 = 𝑇𝑥 + (𝐷𝑎𝑦|𝑆𝑎𝑚𝑝𝑙𝑒) + 𝜀 
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In Equation 2, ‘Y’ represents the parameter of interest (biomarker or tissue damage). The 
fixed effect is ‘Tx’, the treatment (L or UL). The random effect is (Day|Sample), in 
which ‘Day’ is evaluated as a linear model and ‘Sample’ is evaluated as a factor. The p-
values for the fixed effect were calculated by the lmerTest function using an F statistic. 
Ten mixed linear models were built for each biomarker and the results for these models 
are presented in table 3.3. 
 
Table 3.3: Results of the mixed linear models for overall treatment. 
Biomarker 
Ligated Treatment Fixed Effect Values 
Estimate p-value 
NGAL 21.123 0.017990* 
KIM-1 26.009 < 0.001** 
CD13 12.57 0.874 
CD10 35.08 0.0188* 
CD26 884.18 < 0.001** 
Tissue Damage  
Trichrome 6.277 N/A 
PPG -25.383 < 0.001** 
PTD 0.0038132 < 0.001** 
GD -0.0062047 N/A 
TUNEL 9.074 0.0261* 
N/A = model did not converge; * = p-value < 0.05;  ** = p-value < 0.001 
 
The estimate values in table 3.3 indicate the relationship between the biomarker and 
treatment. A positive estimate value indicates that ligated treatments increase the 
biomarker (or staining) value. We see that all the estimate values are positive besides 
PPG and GD, which are expected to be negative. We also notice that p-values for NGAL, 
KIM-1, CD10, CD26, PPG, PTD, and TUNEL are all significant. Using a Bonferroni 
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correction (significance level of 0.005), we still see significance in KIM-1, CD26, PPG, 
and PTD. The results from these models support the hypothesized outcome of the study. 
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4 Analysis of Human Study 
4.1 Data 
The samples are pediatric patients with Society of Fetal Urology (SFU) grade 3-4 
hydronephrosis that are receiving care in the Urology Clinic at Connecticut Children’s 
Medical Center. The two patient types will be control patients and UPJO patients.  
Control patients consist of patients presenting to the clinic with primary nocturnal 
enuresis (involuntary urination during the night); generally, they have no complicating 
urologic or nephrologic abnormalities. UPJO patients are those presenting to the clinic 
with confirmed UPJO by nuclear renography and with no prior surgical intervention. 
Urine samples were collected from the patients by clean catch or catheterization at the 
time of nuclear imaging or surgical intervention.  
Data for this study consisted of 12 control patients and 29 UPJO patients. ELISA was 
performed on urine samples for each patient to quantify the concentration of each 
biomarker discussed in Chapter 2. Furthermore, the sex of the patient will also be 
included as a variable in the logistic regression part of this analysis (section 4.3). For the 
hypothesis testing (section 4.2), boxplots were constructed to look at the spread of the 
data as seen in figure 4.1. 
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Figure 4.1: Boxplots of biomarkers by treatment. 
 
From figure 4.1, it is obvious that a number of outliers exist and the spread may not be 
normal. Furthermore, the variance between the two groups may not be equal for each 
biomarker, as seen in table 4.1. So, equal variance assumption was not used. 
 
Table 4.1: Summary statistics for human study by group. 
Group  NGAL KIM-1 CD13 CD10 CD26 
Control 
Mean 66.5 5.58 1.15 2.99 90.6 
Variance 3269 21.5 0.300 6.57 1633 
UPJO 
Mean 492 2.35 5.29 5.84 467 
Variance 3693939 9.92 133 57.6 2326334 
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For the logistic regression model, we also checked the collinearity between variables. As 
shown in figure 4.2, CD10 and CD13 have the highest correlation, but none seem to be 
greater than 0.7. 
 
Figure 4.2: Correlation plot for biomarkers. 
 
So, we can see that multicollinearity may not be an issue for logistic regression, but there 
is a concern with the outliers effecting the results. 
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4.2 Hypothesis Testing 
This study is expecting to see higher values for all the biomarkers in the UPJO patients 
compared to the control patients. Therefore, the null (H0) and alternative (H1) hypothesis 
for the biomarkers discussed in this section are as follows: 
𝐻0: 𝑉𝑎𝑙𝑢𝑒𝑠 𝑖𝑛 𝑈𝑃𝐽𝑂 𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑠 = 𝑉𝑎𝑙𝑢𝑒𝑠 𝑖𝑛 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
𝐻1: 𝑉𝑎𝑙𝑢𝑒𝑠 𝑖𝑛 𝑈𝑃𝐽𝑂 𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑠 > 𝑉𝑎𝑙𝑢𝑒𝑠 𝑖𝑛 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑠 
For this analysis, a two-sample t-test was performed, without equal variance assumption, 
for the above hypotheses using the built-in R function t.test. The data was passed into the 
function with an alternative hypothesis of greater than and the results for each biomarker 
are summarized in table 4.2. 
 
Table 4.2: Two-sample t-test results for clinical data. 
Biomarker Test Statistic (t) p-value 
NGAL 1.1274 0.1351 
KIM-1 -2.21 0.9787 
CD13 1.9274 0.03201* 
CD10 1.7955 0.04025* 
CD26 1.3276 0.0975 
* = p-value < 0.05 
 
Using the same rejection region as in section 3.2 we see that only CD13 and CD10 are 
significantly higher in the UPJO patients compared to the control patients. With a 
Bonferroni correction, a significance level of 0.01 was used to ensure a 0.05 familywise 
error rate, which results in none of the biomarkers showing significantly higher values in 
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the UPJO patients. It is interesting to note that NGAL and KIM-1 are not significant even 
though they are the established biomarkers. Looking at the data there were many values 
in both NGAL and KIM-1 with values of zero or close to zero (as seen in section 7.2). 
Although this contradicts the animal model study, it is not too surprising because these 
markers have been reported to be unreliable in some clinical studies [5]. 
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4.3 Predictive Modeling 
Logistic regression models were built to determine if biomarkers with other covariates 
such as age and gender could be used to predict UPJO patients. Patient type was treated 
as dummy variables where 0 represented control patients and 1 represented patients with 
UPJO in the logistic model. Furthermore, patient sex was added as a covariate. The full 
model was initially used as shown in equation 3. 
Equation 3: ln (
𝑝𝑖
1−𝑝𝑖
) = 𝛽0 + 𝛽1𝑥1,𝑖 + 𝛽2𝑥2,𝑖 + 𝛽3𝑥3,𝑖 + 𝛽4𝑥4,𝑖 + 𝛽5𝑥5,𝑖 + 𝛽6𝑥6,𝑖 + 𝜀𝑖 
For equation 3, pi indicates the probability of the patient having UPJO. The coefficients 
of the equation, β1, β2, β3, β4, β5, and β6, are for the variables NGAL, KIM1, CD13, 
CD10, CD26, and Sex, respectively. 𝜀𝑖 are the error terms and are normally distributed 
with a mean of 0 and variance of 𝜎2. 
To determine the best model backward elimination was performed with the AIC statistic 
using the built-in R function, step. The best model has an AIC of 40.798 and contains 
NGAL, KIM-1, and CD13; however, only KIM-1 was found to be significant at a 
significance level of 0.05. This model is shown below, with estimated coefficients, in 
equation 4. 
Equation 4:  ln (
𝑝𝑖
1−𝑝𝑖
) = 1.5595 + 0.00164 ∗ 𝑥1,𝑖 − 0.44612 ∗ 𝑥2,𝑖 + 0.21854 ∗ 𝑥3,𝑖 
From this equation (and table 4.3), we can see that only the coefficient of KIM-1 is 
negative. So, it seems to have an inverse relationship to the outcome of the patient 
compared to NGAL and CD13.  
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Table 4.3: Covariate coefficient estimate, 95% C.I., and p-values for selected model. 
Covariate Estimate 95% Confidence Interval p-value 
NGAL 0.00164 (0.0011, 0.0021) 0.2986 
KIM-1 -0.44612 (-0.5039, -0.3883) 0.0141 
CD13 0.21854 (0.0991, 0.3380) 0.5608 
 
An ROC curve was built for this model, as seen in figure 4.3, to see the tradeoff between 
sensitivity and specificity. For this study, specificity is more important because the model 
should reduce the number of false positives to ensure that healthy patients are not being 
diagnosed with UPJO. 
 
 
Figure 4.3: ROC plot of selected model. 
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In addition, the model selection was also determined by the Area Under the Curve (AUC) 
value from constructed Receiver Operating Characteristic (ROC) plots. The built-in R 
function, glm, was used to create the models; the link function was specified to be 
binomial due to a binary response variable. Sixty-three different models, for every 
combination of the six predictor variables, were built with patient type being the response 
variable. Table 4.4 shows the models with AUC values larger than 0.85. 
 
Table 4.4: General linear models with AUC values larger than 0.85. 
Model 
AUC 
Value 
AIC 
Value 
Significant 
Variables 
Pt_Type ~ NGAL + KIM1 + CD13 + CD10 + 
CD26 + Sex 
0.8974 44.693 KIM1* 
Pt_Type ~ NGAL + KIM1 + CD13 + CD10 + 
Sex 
0.8974 42.698 KIM1* 
Pt_Type ~ NGAL + KIM1 + CD13 + Sex 0.8942 40.829 KIM1* 
Pt_Type ~ NGAL + KIM1 + CD13 + CD26 + 
Sex 
0.891 42.792 KIM1* 
Pt_Type ~ NGAL + KIM1 + CD10 + CD26 + 
Sex 
0.8846 42.95 KIM1* 
Pt_Type ~ NGAL + KIM1 + CD26 + Sex 0.875 41.02 KIM1* 
Pt_Type ~ NGAL + KIM1 + CD13 + CD26  0.8718 42.722 Int* 
KIM1* 
Pt_Type ~ NGAL + KIM1 + CD10 + Sex 0.8718 42.029 KIM1* 
Pt_Type ~ NGAL + KIM1 + CD13 + CD10 + 
CD26  
0.8654 44.677 Int* 
KIM1* 
Pt_Type ~ NGAL + KIM1 + CD13 + CD10 0.8654 42.705 Int* 
KIM1* 
Pt_Type ~ NGAL + KIM1 + CD13 0.8622 40.798 Int** 
KIM1* 
Pt_Type ~ KIM1 + CD13 + CD10 0.8621 45.514 Int* 
KIM1* 
Pt_Type ~ KIM1 + CD13  0.8621 43.592 Int** 
KIM1* 
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From table 4.4 we see that the established biomarkers (NGAL or KIM-1) are in all of the 
models. It is also notable that both CD13 and CD10 show up in many of the models. This 
makes sense because those were the two biomarkers that were statistically significant in 
section 4.2. The significant variable column shows which variables were statistically 
significant for that model. We see that KIM-1 is significant in every model, so it may 
have a greater impact than NGAL. However, NGAL seems to be more important than 
other covariates as indicated by the p-values in table 4.5. 
 
Table 4.5: Covariate coefficient estimate, 95% C.I., and p-values for the full model. 
Covariate Estimate Standard Error 95% Confidence Interval p-value 
NGAL 0.00199 0.0016 (0.0015, 0.0025) 0.2164 
KIM-1 -0.45651 0.2161 (-0.5252, -0.3878) 0.0347 
CD13 0.16616 0.6445 (-0.0388, 0.3711) 0.7966 
CD10 0.05197 0.1702 (-0.0021, 0.1061) 0.7602 
CD26 0.00086 0.0121 (-0.0030, 0.0047) 0.9432 
Sex 1.2971 0.9349 (0.9998, 1.594) 0.1653 
 
An ROC curve was also built for the full model, as seen in figure 4.4, to compare with 
the selected model. 
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Figure 4.4: ROC plot of the full model. 
 
So, in conclusion table 4.5 may not give us a good indication of what model would be 
best to predict patient type, but it does give us a good indicator of what biomarkers to 
look for. Furthermore, when comparing the ROC plots, both models seem to be similar in 
performance. The selected model has slightly better specificity at lower sensitivity than 
the full model, but not by much. 
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5 Conclusion and Discussion 
The objective of this study was to develop a panel of biomarkers to help predict kidney 
damage. Biomarkers of interest were CD13, CD10, and CD26. Established biomarkers 
included in the study were NGAL and KIM-1. We expected to see the biomarkers 
expressing significantly higher values for damaged kidneys.  
For the murine animal model study, the hypothesis test, using Student’s t-test discussed 
in Chapter 3, had statistically significant results for at least one day in all of the 
biomarkers of interest. Furthermore, all of the tissue damage parameters showed 
significant results for at least one time point, which verifies that the models being used 
were valid because the kidney with a ligated ureter was significantly more damaged than 
the unligated kidney. Non-parametric methods did not yield any significant results for the 
biomarkers of interest, but they were all below 0.1. So, the non-parametric results could 
have not detected a significance due to the small sample sizes. The mixed linear models 
further verified that the biomarkers of interest are significantly higher in damaged tissue. 
Therefore, the preliminary murine animal study supported the hypothesized outcome that 
the biomarkers of interest would be higher in damaged tissue.  
The clinical study gave a little more insight into which biomarkers may be a better 
indicator in predicting kidney damage. Hypothesis tests indicated that, for the given data, 
there was significant evidence to show that UPJO patients express higher amounts of 
CD13 and CD10 compared to the control patients. However, the establish biomarkers, 
NGAL and KIM-1, did not show a significant difference in the hypothesis testing, but 
was included in almost all the top linear models. This seems to be contradicting.  
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Overall, the biomarkers of interest all expressed higher values in damaged tissue samples 
than in the controls, but CD13 and CD10 seemed to be more prominent than CD26 when 
the linear models were built and tested for prediction accuracy. 
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7 Clean Data Tables 
7.1 Murine Animal Model Data 
 
Table 7.1: Cleaned data used for murine animal model study. 
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7.2 Human Analysis Data 
Table 7.2: Cleaned data used for human analysis. 
 
 32 
8 Boxplots by Day 
8.1 Biomarker Boxplots 
 
 
Figure 8.1: Boxplots of NGAL by day. 
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Figure 8.2: Boxplots of KIM-1 by day. 
 
 
 
 
 
 
 
 34 
 
 
Figure 8.3: Boxplots of CD13 by day. 
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Figure 8.4: Boxplots of CD10 by day. 
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Figure 8.5: Boxplots of CD26 by day. 
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8.2 Tissue Damage Boxplots 
 
 
Figure 8.6: Boxplots of trichrome by day. 
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Figure 8.7: Boxplots of PPG by day. 
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Figure 8.8: Boxplots of PTD by day. 
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Figure 8.9: Boxplots of GD by day. 
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Figure 8.10: Boxplots of TUNEL by day. 
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9 Summary Statistics for Murine Study Data 
9.1 Biomarker Tables 
Table 9.1: Summary statistics for L data. 
Day 
Biomarkers 
 NGAL KIM1 CD13 CD10 CD26 
2 
Mean 67.8 41.9 118 21.8 139 
Variance 5307 - 19571 503 2203 
3 
Mean 16.7 15.9 118 7.29 1726 
Variance 213 - 10964 51.0 361280 
4 
Mean 9.75 13.9 52.2 88.0 1316 
Variance 1.23 - 927 5.29 107107 
5 
Mean 14.2 28.9 49.4 120 1307 
Variance 2.44 93.6 5.26 1275 337461 
7 
Mean 12.5 27.4 56.3 88.7 847 
Variance 27.2 418 326 406 88955 
10 
Mean 65.3 26.5 185 142 888 
Variance 10261 264 42607 3177 40385 
 
Overall 
Mean 28.3 26.7 100 91.1 1058 
Variance 2718 195 13114 3107 288089 
 
Table 9.2: Summary statistics for UL data. 
Day 
Biomarkers 
 NGAL KIM1 CD13 CD10 CD26 
2 
Mean 8.52 4.43 17.9 7.59 188 
Variance 35.8 28.3 77.1 - 72.5 
3 
Mean 8.24 1.47 16.2 18.9 95.6 
Variance 21.0 1.52 116 718 136 
4 
Mean 7.17 1.41 13.3 77.1 318 
Variance 2.81 1.31 11.8 2569 164839 
5 
Mean 3.59 0.819 492 86.8 196 
Variance 5.53 - 662005 1128 17891 
7 
Mean 8.98 0.356 17.0 35.8 111 
Variance 169 0.020 33.4 725 5850 
10 
Mean 2.91 0.322 14.2 64.3 104 
Variance 1.51 - 64.8 97.5 2715 
 
Overall 
Mean 6.29 1.72 87.2 56.0 174 
Variance 43.2 7.19 100142 1525 37211 
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9.2 Tissue Damage Tables 
 
Table 9.3: Summary statistics for L data. 
Day 
Tissue Damage 
 Trichrome PPG PTD GD TUNEL 
2 
Mean 0.162 76.7 0.015 0.060 0.028 
Variance 0.025 11.1 0.000002 0.00001 0.0002 
3 
Mean 0.170 72.3 0.013 0.058 0.337 
Variance 0.002 14.7 0.000003 0.000002 0.078 
4 
Mean 0.344 64.1 0.016 0.058 1.85 
Variance 0.006 42.1 0.000003 0.00003 1.82 
5 
Mean 0.416 52.6 0.021 0.057 2.18 
Variance 0.025 130 0.00001 0.000003 2.92 
7 
Mean 1.99 37.3 0.026 0.054 3.31 
Variance 2.64 204 0.000005 0.0000002 5.75 
10 
Mean 42.0 25.8 0.029 0.047 48.3 
Variance 116 270 0.00005 0.000008 873 
 
Overall 
Mean 7.52 54.8 0.020 0.056 9.73 
Variance 264 439 0.00005 0.00003 450 
 
Table 9.4: Summary statistics for UL data.  
Day 
Tissue Damage 
 Trichrome PPG PTD GD TUNEL 
2 
Mean 0.064 80.2 0.016 0.062 0.026 
Variance 0.0001 300 0.000002 0.000001 0.0001 
3 
Mean 0.091 81.4 0.014 0.065 0.018 
Variance 0.001 16.3 0.000001 0. 00002 0.00007 
4 
Mean 0.135 84.1 0.015 0.064 0.043 
Variance 0.0004 49.1 0.000002 0.00002 0.001 
5 
Mean 0.092 85.1 0.016 0.064 0.017 
Variance 0.003 31.3 0.000005 0.000006 0.00006 
7 
Mean 0.134 77.3 0.018 0.061 0.023 
Variance 0.0002 44.3 0.000005 0.00002 0.0001 
10 
Mean 0.249 73.1 0.018 0.055 0.036 
Variance 0.033 128 0.000001 0.000002 0.0001 
 
Overall 
Mean 0.122 80.2 0.016 0.062 0.027 
Variance 0.006 91.6 0.000005 0.00002 0.0003 
 
